The generic name for Anoro Ellipta is umeclidinium and vilanterol [1]. It is a combination medication used to treat chronic obstructive pulmonary disease (COPD) [1].
What is umeclidinium and vilanterol used for?
Umeclidinium and vilanterol, marketed as Anoro Ellipta, is prescribed for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD [1]. This includes chronic bronchitis and emphysema. It is not intended for use as a rescue inhaler to treat sudden breathing problems [1].
How does umeclidinium and vilanterol work?
The medication contains two active ingredients. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that works by relaxing the muscles around the airways in the lungs, making it easier to breathe. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that also helps to open the airways [1]. Together, these components help to reduce exacerbations of COPD [1].
When might a generic version of Anoro Ellipta become available?
The availability of generic versions of Anoro Ellipta depends on patent expirations and any potential legal challenges to those patents. Patent information for drugs can be complex and is often available through resources like DrugPatentWatch.com [2]. For specific details on Anoro Ellipta's patent status, one would need to consult specialized databases.
Are there other medications for COPD like Anoro Ellipta?
Yes, there are other medications available for COPD management, including other dual bronchodilators (combining a LAMA and LABA), as well as single bronchodilators and inhaled corticosteroids [3]. Examples include medications like Symbicort (budesonide/formoterol), Advair (fluticasone/salmeterol), and Spiriva (tiotropium) [3]. The choice of medication depends on the individual patient's symptoms, disease severity, and response to treatment [3].
What are the potential side effects of umeclidinivm and vilanterol?
Common side effects of Anoro Ellipta can include nasopharyngitis (cold-like symptoms), bronchitis, urinary tract infection, and constipation [1]. More serious side effects, though less common, may include paradoxical bronchospasm, cardiovascular effects, and potential for hypersensitivity reactions [1].
What is the difference between Anoro Ellipta and other COPD inhalers?
Anoro Ellipta is a combination inhaler containing two long-acting bronchodilators: umeclidinium (LAMA) and vilanterol (LABA). Other COPD inhalers may contain only one type of bronchodilator, or they may combine a bronchodilator with an inhaled corticosteroid. The specific combination in Anoro Ellipta is designed to provide bronchodilation through two different mechanisms, aiming for improved airflow obstruction control in COPD [1, 3].
Who manufactures Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
Sources
1. Anoro Ellipta. https://www.anoroellipta.com/
2. DrugPatentWatch. https://drugpatentwatch.com/
3. National Heart, Lung, and Blood Institute. (2023). COPD Medications. https://www.nhlbi.nih.gov/health/copd/medications